CO2022015170A2 - Composiciones que comprenden una variante del polipéptido cas12i2 y usos de las mismas - Google Patents

Composiciones que comprenden una variante del polipéptido cas12i2 y usos de las mismas

Info

Publication number
CO2022015170A2
CO2022015170A2 CONC2022/0015170A CO2022015170A CO2022015170A2 CO 2022015170 A2 CO2022015170 A2 CO 2022015170A2 CO 2022015170 A CO2022015170 A CO 2022015170A CO 2022015170 A2 CO2022015170 A2 CO 2022015170A2
Authority
CO
Colombia
Prior art keywords
cas12i2
polypeptide variants
compositions
complexes
polypeptide variant
Prior art date
Application number
CONC2022/0015170A
Other languages
English (en)
Spanish (es)
Inventor
Shaorong Chong
Brendan Jay Hilbert
Quinton Norman Wessells
Noah Michael Jakimo
Roy Ziblat
Jason Michael Carte
Tia Marie Ditommaso
Jeffrey Raymond Haswell
Anthony James Garrity
Colin Alexander Mcgaw
David A Scott
Derek Michael Cerchione
Original Assignee
Arbor Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arbor Biotechnologies Inc filed Critical Arbor Biotechnologies Inc
Publication of CO2022015170A2 publication Critical patent/CO2022015170A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2022/0015170A 2020-03-31 2022-10-25 Composiciones que comprenden una variante del polipéptido cas12i2 y usos de las mismas CO2022015170A2 (es)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US202063003090P 2020-03-31 2020-03-31
US202063002999P 2020-03-31 2020-03-31
US202063003064P 2020-03-31 2020-03-31
US202063012007P 2020-04-17 2020-04-17
US202063026277P 2020-05-18 2020-05-18
US202063026606P 2020-05-18 2020-05-18
US202063026562P 2020-05-18 2020-05-18
US202063026523P 2020-05-18 2020-05-18
US202063063879P 2020-08-10 2020-08-10
US202063063831P 2020-08-10 2020-08-10
US202063063859P 2020-08-10 2020-08-10
US202063063819P 2020-08-10 2020-08-10
US202063085862P 2020-09-30 2020-09-30
US202063085895P 2020-09-30 2020-09-30
US202063085752P 2020-09-30 2020-09-30
US202063085792P 2020-09-30 2020-09-30
US202163147968P 2021-02-10 2021-02-10
US202163147850P 2021-02-10 2021-02-10
PCT/US2021/025257 WO2021202800A1 (en) 2020-03-31 2021-03-31 Compositions comprising a cas12i2 variant polypeptide and uses thereof

Publications (1)

Publication Number Publication Date
CO2022015170A2 true CO2022015170A2 (es) 2022-11-08

Family

ID=75640000

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0015170A CO2022015170A2 (es) 2020-03-31 2022-10-25 Composiciones que comprenden una variante del polipéptido cas12i2 y usos de las mismas

Country Status (12)

Country Link
US (1) US20230332119A1 (cg-RX-API-DMAC7.html)
EP (1) EP4127154A1 (cg-RX-API-DMAC7.html)
JP (1) JP7881475B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230009379A (cg-RX-API-DMAC7.html)
CN (2) CN115698278B (cg-RX-API-DMAC7.html)
AU (1) AU2021249119A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022019713A2 (cg-RX-API-DMAC7.html)
CA (1) CA3177749A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022015170A2 (cg-RX-API-DMAC7.html)
IL (1) IL296791A (cg-RX-API-DMAC7.html)
MX (1) MX2022012189A (cg-RX-API-DMAC7.html)
WO (1) WO2021202800A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
US20230193243A1 (en) * 2020-05-29 2023-06-22 Arbor Biotechnologies, Inc. Compositions comprising a cas12i2 polypeptide and uses thereof
EP4237557A1 (en) * 2020-10-30 2023-09-06 Arbor Biotechnologies, Inc. Compositions comprising an rna guide targeting pdcd1 and uses thereof
TW202246497A (zh) * 2021-01-20 2022-12-01 美商阿伯生物技術公司 Cas12i2融合分子及其用途
AU2022284804A1 (en) * 2021-06-01 2023-12-07 Arbor Biotechnologies, Inc. Gene editing systems comprising a crispr nuclease and uses thereof
KR20240034746A (ko) 2021-06-04 2024-03-14 아버 바이오테크놀로지스, 인크. 하이드록시산 산화효소 1(hao1)을 표적으로 하는 rna 가이드를 포함하는 유전자 편집 시스템 및 이의 용도
WO2022256655A2 (en) 2021-06-04 2022-12-08 Arbor Biotechnologies, Inc. Gene editing systems comprising an rna guide targeting lactate dehydrogenase a (ldha) and uses thereof
US20220396782A1 (en) 2021-06-04 2022-12-15 Arbor Biotechnologies, Inc. Gene editing systems comprising an rna guide targeting transthyretin (ttr) and uses thereof
KR20240052763A (ko) * 2021-08-11 2024-04-23 아버 바이오테크놀로지스, 인크. 스타스민 2 (stmn2)를 표적화하는 rna 가이드를 포함하는 유전자 편집 시스템 및 이의 용도
WO2023018856A1 (en) 2021-08-11 2023-02-16 Arbor Biotechnologies, Inc. Gene editing systems comprising an rna guide targeting polypyrimidine tract binding protein 1 (ptbp1) and uses thereof
WO2023034475A1 (en) 2021-09-01 2023-03-09 Arbor Biotechnologies, Inc. Cells modified by a cas12i polypeptide
EP4399293A4 (en) * 2021-09-10 2025-10-15 Arbor Biotechnologies Inc COMPOSITIONS COMPRISING A CAS12I POLYPEPTIDE AND USES THEREOF
AU2022382751A1 (en) * 2021-11-02 2024-05-23 Huidagene Therapeutics (Singapore) Pte. Ltd. Novel crispr-cas12i systems and uses thereof
WO2023081377A2 (en) * 2021-11-05 2023-05-11 Arbor Biotechnologies, Inc. Compositions comprising an rna guide targeting ciita and uses thereof
WO2023122433A1 (en) 2021-12-22 2023-06-29 Arbor Biotechnologies, Inc. Gene editing systems targeting hydroxyacid oxidase 1 (hao1) and lactate dehydrogenase a (ldha)
WO2023138685A1 (en) * 2022-01-24 2023-07-27 Huidagene Therapeutics Co., Ltd. Novel crispr-cas12i systems and uses thereof
EP4514954A4 (en) * 2022-04-25 2026-03-25 Huidagene Therapeutics Singapore Pte Ltd NEW CRISPR-CAS12I SYSTEMS AND THEIR USES
EP4627083A1 (en) 2022-11-30 2025-10-08 Arbor Biotechnologies, Inc. Reverse transcriptase-mediated genetic editing of transthyretin (ttr) and uses thereof
US20260232844A1 (en) 2023-02-15 2026-08-13 Arbor Biotechnologies, Inc. Gene editing method for inhibiting aberrant splicing in stathmin 2 (stmn2) transcript
WO2025096594A2 (en) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Cells expressing anti-cd19 chimeric antigen receptors and methods of use thereof
CN117431235A (zh) * 2023-11-06 2024-01-23 微光基因(苏州)有限公司 CRISPR-Cas系统及其应用
WO2025147604A1 (en) 2024-01-05 2025-07-10 Arbor Biotechnologies, Inc. Methods for treating primary hyperoxaluria via genetic editing of hydroxyacid oxidase 1
WO2025171210A1 (en) 2024-02-09 2025-08-14 Arbor Biotechnologies, Inc. Compositions and methods for gene editing via homology-mediated end joining
WO2026015832A2 (en) 2024-07-12 2026-01-15 Arbor Biotechnologies, Inc. Reverse transcriptases and gene editing systems comprising such
WO2026015829A2 (en) 2024-07-12 2026-01-15 Arbor Biotechnologies, Inc. Small reverse transcriptases and gene editing systems comprising such
CN120424908B (zh) * 2025-07-10 2025-09-12 南京农业大学 一种基于LAMP与CRISPR/Cas的检测方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201707569YA (en) 2012-12-12 2017-10-30 Broad Inst Inc Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
WO2014204725A1 (en) * 2013-06-17 2014-12-24 The Broad Institute Inc. Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
CN111218447B (zh) 2013-11-07 2024-10-11 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
PL3765615T3 (pl) * 2018-03-14 2023-11-13 Arbor Biotechnologies, Inc. Nowe enzymy i układy crispr ukierunkowane na dna
EP3924479A4 (en) * 2019-02-13 2023-01-25 Beam Therapeutics, Inc. ADENOSINE DEAMINASE BASE EDITORS AND METHODS OF USING THEM TO MODIFY A NUCLEOBASE IN A TARGET SEQUENCE
WO2024178144A1 (en) * 2023-02-22 2024-08-29 Prime Medicine, Inc. Methods and compositions for editing nucleotide sequences

Also Published As

Publication number Publication date
KR20230009379A (ko) 2023-01-17
BR112022019713A2 (pt) 2022-12-20
WO2021202800A1 (en) 2021-10-07
IL296791A (en) 2022-11-01
CN115698278B (zh) 2025-10-17
JP7881475B2 (ja) 2026-06-29
CN121380024A (zh) 2026-01-23
CN115698278A (zh) 2023-02-03
MX2022012189A (es) 2023-01-05
US20230332119A1 (en) 2023-10-19
CA3177749A1 (en) 2021-10-07
AU2021249119A1 (en) 2022-10-20
EP4127154A1 (en) 2023-02-08
JP2023520504A (ja) 2023-05-17

Similar Documents

Publication Publication Date Title
MX2022012189A (es) Composiciones que comprenden una variante del polipéptido cas12i2 y usos de las mismas.
MX2023014120A (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentradas de baja viscosidad, kits, y metodos.
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
CO2018010715A2 (es) Compuestos bicíclicos
CL2019001293A1 (es) Agentes, usos y métodos para el tratamiento de la sinucleinopatía.
MX2023010508A (es) Composiciones que comprenden un polipéptido variante y usos de las mismas.
SV2018005612A (es) Agentes, usos y metodos para el tratamiento de la sinucleinopatia
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
MX386520B (es) Polimorfos de sepiapterina y sales de los mismos.
MX2019011778A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma.
CL2021000938A1 (es) Composiciones estables de semaglutida y usos de las mismas
CL2019003213A1 (es) Compuestos plaguicidas bicíclicos.
CO2021005509A2 (es) Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos
AR120057A1 (es) Composiciones neoantigénicas y usos de estas
UY39390A (es) Forma amorfa de un inhibidor de la malt1 y formulaciones del mismo
MX2019013293A (es) Composiciones y productos de fragancia novedosos con efectos mejoradores del estado de animo.
UY40418A (es) Métodos y composiciones para mejorar características de rendimiento en plantas
CO2020012963A2 (es) Composición farmacéutica y método de fabricación
MX2024010977A (es) Composiciones que comprenden aticaprant
CO2021007172A2 (es) Sales cristalinas de un inhibidor de calicreína plasmática
CO2023011697A2 (es) Composiciones que comprenden un polipéptido cas12i4 variante y usos de las mismas
MX2025009863A (es) Formulaciones solidas y formas polimorficas de inhibidores de indolina de kif18a
MX2025014063A (es) Inhibidores de expresion y/o funcion
CO2019014831A2 (es) Nuevas formulaciones orales de belinostat
PY2107343A (es) Supresión de la respuesta de escape a la sombra en plantas